Skip to main content

Anti-Rheumatic Rx

ACR Best
On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these as their favorite reports: DAS-28 independently associated survival in RA-ILD. As I keep saying, treating the rheumatoid…
EULAR19.abstract.jpg (keep)
Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis. Abstract 1424 – Dr. Hermine…
RT @ericdeinmd: Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict wh

Eric Dein ericdeinmd

9 months 1 week ago
Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict which patients are most likely to have nausea or alopecia intolerance to MTX?https://t.co/I5WmCECq7v
RT @uptoTate: Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use

Dr. Rachel Tate uptoTate

9 months 1 week ago
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
RT @doctorRBC: Methotrexate did not improve Ustekinumab efficacy in tx of PsA
⭐️Addition of MTX did not improve dact

Robert B Chao, MD doctorRBC

9 months 1 week ago
Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
RT @RichardPAConway: No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthr

Richard Conway RichardPAConway

9 months 1 week ago
No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
×